In the FTC’s first merger challenge of the new administration, the FTC voted 4-0 last week to challenge the proposed ...
GlobalData on MSN4d
FTC sues to block GTCR’s ‘unlawful acquisition’ of SurmodicsGTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...
On March 6, 2025, the Federal Trade Commission (FTC) filed a lawsuit in federal court challenging GTCR BC Holdings, LLC's (GTCR) proposed ...
Surmodics (NASDAQ:SRDX) fell 4.6% after the Federal Trade Commission filed a lawsuit to block its planned $627 million sale ...
The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...
Lake Street analyst Brooks O’Neil upgraded Surmodics (SRDX) to Buy from Hold with an unchanged price target of $43. The Federal Trade ...
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court. EDEN PRAIRIE, Minn., ...
Surmodics (NASDAQ:SRDX) edged lower by 0.7% amid a report that it's scheduled to meet with regulators this week to convince ...
Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.
The U.S. Federal Trade Commission (FTC) has sued to block the planned acquisition of medical device company Surmodics (Nasdaq ...
The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...
Fintel on MSN6d
Lake Street Upgrades Surmodics (SRDX)Fintel reports that on March 7, 2025, Lake Street upgraded their outlook for Surmodics (NasdaqGS:SRDX) from Hold to Buy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback